Dose Individualization of Pemetrexed - IMPROVE-III

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2019

Primary Completion Date

September 20, 2020

Study Completion Date

August 1, 2021

Conditions

Non Small Cell Lung CancerMesothelioma

Interventions

DRUG

Pemetrexed

patients will be administered a microdose with subsequent pharmacokinetic assessment.

Trial Locations (5)

Jeroen Bosch Hospital, 's-Hertogenbosch

Antoni van Leeuwenhoek, Amsterdam

Maastricht University Medical centre, Maastricht

Radboud university medical centre, Nijmegen

Erasmus University Medical Centre, Rotterdam

All Listed Sponsors

collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

lead

Radboud University Medical Center

OTHER

NCT03655834 - Dose Individualization of Pemetrexed - IMPROVE-III | Biotech Hunter | Biotech Hunter